FVR Kokkolan rokotetutkimusklinikka

Research site

Finland Rantakatu 16, 67100 Kokkola, Finland

1 trial recruiting
Pneumococcal immunisation
Children and adolescents

About Specializations

FVR Kokkolan rokotetutkimusklinikka in Kokkola, Finland specialises in clinical trials of conditions such as Pneumococcal immunisation, and other specialisations. This site conducts important research.

Pneumococcal immunisation

Main research areas of the site

Bacterial Infections and Mycoses – Pneumococcal Immunisation

The site focuses on Bacterial Infections and Mycoses with a specific emphasis on pneumococcal immunisation, aiming to evaluate the safety and immune response of a new pneumococcal vaccine in children and infants.

Safety profiling of the PG4 pneumococcal vaccine
Assessment of tolerability in healthy pediatric populations
Characterisation of immune response in infants and adolescents

At FVR Kokkolan rokotetutkimusklinikka, researchers are gathering data to support future vaccine development and improve preventative strategies against bacterial lung infections.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Rantakatu 1667100 KokkolaFinland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 1

More sites in Kokkola Finland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal immunisation

Not yet recruiting

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites